Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety in vitro and in vivo: Implication in atherosclerosis

Journal of Biological Chemistry

Volumn 292, Issue 13, 2017, Pages 5378-5391

  Lu, Jianhong ^a,b,c   Guo, Shuyuan ^a,b,c,d   Xue, Xinli ^a,b,c   Chen, Qun ^a,b,c   Ge, Jing ^e   Zhuo, Yujuan ^a,b,c,d   Zhong, Huiqin ^a,b,c   Chen, Buxing ^f   Zhao, Mingming ^g   Han, Wei ^h   Suzuki, Takashi ^h   Zhu, Mingjiang ^a,c   Xia, Lin ^a,c   Schneider, Claus ^h   Blackwell, Timothy S ^h,i   Porter, Ned A ^j   Zheng, Lemin ^g   Tsimikas, Sotirios ^k   Yin, Huiyong ^a,b,c,d  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING HOSPITAL   (China)

^d SHANGHAITECH UNIVERSITY   (China)

^e INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g Peking University   (China)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ DEPARTMENT OF VETERANS AFFAIRS   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CELLULAR MANUFACTURING; CYTOLOGY; DISEASE CONTROL; DRUG PRODUCTS; GENES; MACROPHAGES; MASS SPECTROMETRY; OXIDATION; PATHOLOGY; PHOSPHOLIPIDS;

ANTI-OXIDANT RESPONSE; CARDIO-VASCULAR DISEASE; CORONARY HEART DISEASE; LOW DENSITY LIPOPROTEINS; OXIDIZED PHOSPHOLIPIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; REPRESENTATIVE COMPOUND; SYSTEMATIC INFLAMMATORY RESPONSE SYNDROMES;

DISEASES;

1 PALMITOYL 2 15 DEOXY DELTA 12,14 PROSTAGLANDIN J2 N GLYCERO 3 PHOSPHOCHOLINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARDIOVASCULAR AGENT; CYCLOPENTENONE; FATTY ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOLIPID; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CYCLOPENTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FOAM CELL; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; MACROPHAGE; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; RNA SEQUENCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSCRIPTOMICS; ANIMAL; ATHEROSCLEROSIS; CHEMISTRY; INFLAMMATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; CYCLOPENTANES; FOAM CELLS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; PHOSPHOLIPIDS; SIGNAL TRANSDUCTION;

EID: 85016571366     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M116.751909     Document Type: Article

References (48)

1. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L. (1989) Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924
2. Steinberg, D., and Witztum, J. L. (2010) Oxidized low-density lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 2311-2316
3. Berliner, J. A., Leitinger, N., and Tsimikas, S. (2009) The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50, S207-S212
4. Berliner, J. A., and Watson, A. D. (2005) A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353, 9-11
5. Salomon, R. G. (2012) Structural identification and cardiovascular activities of oxidized phospholipids. Circ. Res. 111, 930-946
6. Moore, K. J., and Tabas, I. (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341-355
7. Kadl, A., Meher, A. K., Sharma, P. R., Lee, M. Y., Doran, A. C., Johnstone, S. R., Elliott, M. R., Gruber, F., Han, J., Chen, W., Kensler, T., Ravichandran, K. S., Isakson, B. E., Wamhoff, B. R., and Leitinger, N. (2010) Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 107, 737-746
8. Brown, H. A., and Marnett, L. J. (2011) Introduction to lipid biochemistry, metabolism, and signaling. Chem. Rev. 111, 5817-5820
9. Yin, H., Zhou, Y., Zhu, M., Hou, S., Li, Z., Zhong, H., Lu, J., Meng, T., Wang, J., Xia, L., Xu, Y., and Wu, Y. (2013) Role of mitochondria in programmed cell death mediated by arachidonic acid-derived eicosanoids. Mitochondrion 13, 209-224
10. Uchida, K., and Shibata, T. (2008) 15-Deoxy-delta(12,14)-prostaglandin J2: an electrophilic trigger of cellular responses. Chem. Res. Toxicol. 21, 138-144
11. Oh, J. Y., Giles, N., Landar, A., and Darley-Usmar, V. (2008) Accumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defense induction. Biochem. J. 411, 297-306
12. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-108
13. Itoh, K., Mochizuki, M., Ishii, Y., Ishii, T., Shibata, T., Kawamoto, Y., Kelly, V., Sekizawa, K., Uchida, K., and Yamamoto, M. (2004) Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxydelta( 12,14)-prostaglandin j(2). Mol. Cell. Biol. 24, 36-45
14. Yin, H., and Porter, N. A. (2005) New insights regarding the autoxidation of polyunsaturated fatty acids. Antioxid. Redox Signal. 7, 170-184
15. Davies, S. S., Amarnath, V., and Roberts, L. J., 2nd (2004) Isoketals: highly reactive γ-ketoaldehydes formed from the H2-isoprostane pathway. Chem. Phys. Lipids 128, 85-99
16. Fessel, J. P., Porter, N. A., Moore, K. P., Sheller, J. R., and Roberts, L. J., 2nd (2002) Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc. Natl. Acad. Sci. U.S.A. 99, 16713-16718
17. Milne, G. L., Yin, H., Hardy, K. D., Davies, S. S., and Roberts, L. J., 2nd (2011) Isoprostane generation and function. Chem. Rev. 111, 5973-5996
18. McIntyre, T. M., Prescott, S. M., and Stafforini, D. M. (2009) The emerging roles of PAF acetylhydrolase. J. Lipid Res. 50, S255-S259
19. Liu, W., Morrow, J. D., and Yin, H. (2009) Quantification of F2-isoprostanes as a reliable index of oxidative stress in vivo using gas chromatography- mass spectrometry (GC-MS) method. Free Radic. Biol. Med. 47, 1101-1107
20. Milne, S. B., Tallman, K. A., Serwa, R., Rouzer, C. A., Armstrong, M. D., Marnett, L. J., Lukehart, C. M., Porter, N. A., and Brown, H. A. (2010) Capture and release of alkyne-derivatized glycerophospholipids using cobalt chemistry. Nat. Chem. Biol. 6, 205-207
21. Watson, A. D., Leitinger, N., Navab, M., Faull, K. F., Hörkkö, S., Witztum, J. L., Palinski, W., Schwenke, D., Salomon, R. G., Sha, W., Subbanagounder, G., Fogelman, A. M., and Berliner, J. A. (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597-13607
22. Bochkov, V. N., Oskolkova, O. V., Birukov, K. G., Levonen, A.-L., Binder, C. J., and Stöckl, J. (2010) Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal. 12, 1009-1059
23. Bretscher, P., Egger, J., Shamshiev, A., Trötzmüller, M., Köfeler, H., Carreira, E. M., Kopf, M., and Freigang, S. (2015) Phospholipid oxidation generates potent anti-inflammatory lipid mediators that mimic structurally related pro-resolving eicosanoids by activating Nrf2. EMBO Mol. Med. 7, 593-607
24. Ravandi, A., Leibundgut, G., Hung, M. Y., Patel, M., Hutchins, P. M., Murphy, R. C., Prasad, A., Mahmud, E., Miller, Y. I., Dennis, E. A., Witztum, J. L., and Tsimikas, S. (2014) Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J. Am. Coll. Cardiol. 63, 1961-1971
25. Yin, H., Cox, B. E., Liu, W., Porter, N. A., Morrow, J. D., and Milne, G. L. (2009) Identification of intact oxidation products of glycerophospholipids in vitro and in vivo using negative ion electrospray iontrap mass spectrometry. J. Mass Spectrom. 44, 672-680
26. Watson, A. D., Subbanagounder, G., Welsbie, D. S., Faull, K. F., Navab, M., Jung, M. E., Fogelman, A. M., and Berliner, J. A. (1999) Structural identification of a novel proinflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J. Biol. Chem. 274, 24787-24798
27. Ravandi, A., Babaei, S., Leung, R., Monge, J. C., Hoppe, G., Hoff, H., Kamido, H., and Kuksis, A. (2004) Phospholipids and oxophospholipids in atherosclerotic plaques at different stages of plaque development. Lipids 39, 97-109
28. Musiek, E. S., Gao, L., Milne, G. L., Han, W., Everhart, M. B., Wang, D., Backlund, M. G., DuBois, R. N., Zanoni, G., Vidari, G., Blackwell, T. S., and Morrow, J. D. (2005) Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J. Biol. Chem. 280, 35562-35570
29. Schopfer, F. J., Cipollina, C., and Freeman, B. A. (2011) Formation and signaling actions of electrophilic lipids. Chem. Rev. 111, 5997-6021
30. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) 15-Deoxy-delta(12,14)-prostaglandin J2 is a ligand for the adipocyte determination factor PPARα. Cell 83, 803-812
31. Harmon, G. S., Lam, M. T., and Glass, C. K. (2011) PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321-6340
32. Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Febbraio, M., Hajjar, D. P., Silverstein, R. L., Hoff, H. F., Salomon, R. G., and Hazen, S. L. (2002) A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277, 38517-38523
33. Chen, B., Li, J., and Zhu, H. (2016) AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A/NF-κB/LOX-1 pathway. Vascul. Pharmacol. 85, 1-10
34. Lin, C. S., Lin, F. Y., Ho, L. J., Tsai, C. S., Cheng, S. M., Wu, W. L., Huang, C. Y., Lian, C. H., Yang, S. P., and Lai, J. H. (2012) PKCdelta signalling regulates SR-A and CD36 expression and foam cell formation. Cardiovasc. Res. 95, 346-355
35. Yu, X. H., Fu, Y. C., Zhang, D. W., Yin, K., and Tang, C. K. (2013) Foam cells in atherosclerosis. Clin. Chim. Acta 424, 245-252
36. Mendis, S., Davis, S., and Norrving, B. (2015) Organizational update the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke 46, e121-e122
37. Lee, S., Birukov, K. G., Romanoski, C. E., Springstead, J. R., Lusis, A. J., and Berliner, J. A. (2012) Role of phospholipid oxidation products in atherosclerosis. Circ. Res. 111, 778-799
38. Kadl, A., Sharma, P. R., Chen, W., Agrawal, R., Meher, A. K., Rudraiah, S., Grubbs, N., Sharma, R., and Leitinger, N. (2011) Oxidized phospholipidinduced inflammation is mediated by Toll-like receptor 2. Free Radic. Biol. Med. 51, 1903-1909
39. Bochkov, V. N. (2007) Inflammatory profile of oxidized phospholipids. Thromb. Haemost. 97, 348-354
40. Kawamoto, Y., Nakamura, Y., Naito, Y., Torii, Y., Kumagai, T., Osawa, T., Ohigashi, H., Satoh, K., Imagawa, M., and Uchida, K. (2000) Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes: 15-deoxy-delta(12,14)-prostaglandin j2-induced expression of glutathione S-transferases. J. Biol. Chem. 275, 11291-11299
41. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103-118
42. Seno, T., Hamaguchi, M., Ashihara, E., Kohno, M., Ishino, H., Yamamoto, A., Kadoya, M., Nakamura, K., Murakami, K., Matoba, S., Maekawa, T., and Kawahito, Y. (2011) 15-Deoxy-delta-prostaglandin J2 reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice. PLoS ONE 6, e25541
43. Hardy, K. D., Cox, B. E., Milne, G. L., Yin, H., and Roberts, L. J., 2nd (2011) Nonenzymatic free radical-catalyzed generation of 15-deoxy-β12,14- prostaglandin J2-like compounds (deoxy-J2-isoprostanes) in vivo. J. Lipid Res. 52, 113-124
44. Yu, Z., Schneider, C., Boeglin, W. E., and Brash, A. R. (2007) Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARα. Lipids 42, 491-497
45. Cernuda-Morollón, E., Pineda-Molina, E., Cañada, F. J., and Pérez-Sala, D. (2001) 15-Deoxy-delta 12,14-prostaglandin J2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536
46. Vunta, H., Davis, F., Palempalli, U. D., Bhat, D., Arner, R. J., Thompson, J. T., Peterson, D. G., Reddy, C. C., and Prabhu, K. S. (2007) The antiinflammatory effects of selenium are mediated through 15-deoxy-12,14- prostaglandin J2 in macrophages. J. Biol. Chem. 282, 17964-17973
47. Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C. H., Sengchanthalangsy, L. L., Ghosh, G., and Glass, C. K. (2000) 15-Deoxydelta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 97, 4844-4849
48. Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., and Yamamoto, M. (2009) The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol. Cell. Biol. 29, 493-502